Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > US Clinical Study sites
View:
Post by Eoganacht on Oct 20, 2021 5:24pm

US Clinical Study sites

Of the 7 US clinical study sites 5 have no mention of our trial on their clinical study search pages:

Virginia Urology
Urology Associates P.C.
MidLantic Urology
University of Wisconsin-Madison
Urology San Antonio

However the Carolina Urologic Research Center, Myrtle Beach, South Carolina, does list our trial:
https://carolinaurologicresearchcenter.com/current-trials/current-trials-bladder-cancer/

And the University of Chicago Medicine has a description of our trial which is even more detailed than the one on the UHN site.

https://www.uchicagomedicine.org/find-a-clinical-trial/clinical-trial/5/irb201049#headingEligibility
Comment by Johnandrose22 on Oct 20, 2021 8:03pm
From the UChicagoMedicine Trial Site: This is a Phase II, open label, single arm, multicenter study conducted in Canada, the United States and internationally.... Internationally?! Wow...I didn't know. John
Comment by socksnblonds642 on Oct 20, 2021 9:46pm
Guess the devil is in the details, it does say subject to IRB approval. The FDA does not preclude compensation for the IRB auditors. Maybe it takes money to get this done! Maybe they hedged their bet on getting to the magic number of 25 with the sites that are in progress.I saw this a while ago and didn't get too excited. Either delayed with politics, money or the pandemic or all of the above. ...more  
Comment by Oilminerdeluxe on Oct 21, 2021 1:17am
Ugh, I yearn for an update. A fat massive one.
Comment by CAinPlap on Oct 21, 2021 10:30am
This has been my biggest question mark. It would be nice to know what the lack of US trial participation is due to.
Comment by CAinPlap on Oct 21, 2021 10:32am
Could part of the reason be that the TLT cannot offer the same compensation for trial participation that competing trials are offering?  
Comment by TriumphSpitSix on Oct 21, 2021 11:17am
Compenstion? Being cured of cancer isn't good enough?
Comment by Gooseybear on Oct 21, 2021 1:35pm
In the US, experimental procedures aren't typically covered by insurance so unless supported by the company may not happen due to expenses.
Comment by CAinPlap on Oct 21, 2021 4:15pm
I may be wrong but I thought trial participants are often compensated. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250